Biotechnology (53) | Transition Agreements (53)
Browse by Company
-
2seventy bio, Inc. (2)
-
ADMA BIOLOGICS, INC. (2)
-
Alector, Inc. (1)
-
Allena Pharmaceuticals, Inc. (2)
-
Allovir, Inc. (1)
-
Altimmune, Inc. (1)
-
Aptevo Therapeutics Inc. (2)
-
Arcellx, Inc. (1)
-
Arcutis Biotherapeutics, Inc. (1)
-
BioAtla, Inc. (1)
-
bluebird bio, Inc. (3)
-
CANCER GENETICS, INC (1)
-
CONTRAFECT Corp (1)
-
Cyclerion Therapeutics, Inc. (2)
-
Deciphera Pharmaceuticals, Inc. (1)
-
Dicerna Pharmaceuticals Inc (1)
-
FIBROGEN INC (1)
-
Gossamer Bio, Inc. (1)
-
GTX INC (1)
-
iBio, Inc. (1)
-
Karyopharm Therapeutics Inc. (3)
-
Mirum Pharmaceuticals, Inc. (1)
-
Moderna, Inc. (1)
-
NEWLINK GENETICS CORP (1)
-
OncoCyte Corp (1)
-
OPGEN INC (1)
-
PDL BIOPHARMA, INC. (1)
-
Pfenex Inc. (1)
-
Praxis Precision Medicines, Inc. (1)
-
PUMA BIOTECHNOLOGY, INC. (1)
-
Retrophin, Inc. (1)
-
SELECTA BIOSCIENCES INC (3)
-
Sierra Oncology, Inc. (1)
-
Surface Oncology, Inc. (1)
-
Ultragenyx Pharmaceutical Inc. (3)
-
VICAL INC (1)
-
Viela Bio, Inc. (1)
-
Vigil Neuroscience, Inc. (1)
-
XBiotech Inc. (2)
Recent Contracts
-
Transition Agreement and Release, dated as of August 14, 2022, by and between Cara Cassino, M.D. and ContraFect Corporation
(CONTRAFECT Corp, Filed With SEC on August 16, 2022)
-
Amendment to the Transition Services Agreement, by and between 2seventy bio, Inc. and the Registrant
(bluebird bio, Inc., Filed With SEC on August 4, 2022)
-
Transition Agreement dated July 26, 2022, by and between Praxis Precision Medicines, Inc. and Bernard Ravina
(Praxis Precision Medicines, Inc., Filed With SEC on July 26, 2022)
-
Transition Services Agreement, dated as of
(VICAL INC, Filed With SEC on May 3, 2022)
-
Transition Agreement, dated March 28, 2022, between the Company and Michael G. Kauffman
(Karyopharm Therapeutics Inc., Filed With SEC on March 29, 2022)
-
Transition Agreement, dated March 28, 2022, between the Company and Sharon Shacham
(Karyopharm Therapeutics Inc., Filed With SEC on March 29, 2022)
-
Transition Agreement and Release dated March 22, 2022 between the Company and Mark Kowalski
(Sierra Oncology, Inc., Filed With SEC on March 23, 2022)
-
Transition Agreement and Release between the Registrant and David Hilbert, Ph.D., dated January 7, 2022
(Arcellx, Inc., Filed With SEC on January 14, 2022)
-
Transition Agreement, by and between the Registrant and Richard A. Fisher, dated November 17, 2021
(Vigil Neuroscience, Inc., Filed With SEC on November 19, 2021)
-
Executive Transition Services Agreement
(Aptevo Therapeutics Inc., Filed With SEC on November 12, 2021)